Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Carbolithium to Lithiofor in bipolar patients with lithium-induced tremor
2016-001714-14Phase 4Terminated
- Sponsor
- Angelini Pharma
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lithium in bipolar disorder (BD) (2 arms), sponsored by Angelini Pharma. Primary endpoint: Improvement in lithium-induced tremor after 1 week. Started Dec 2019; status: terminated.
02
Drugs
lithium
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2016-001714-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001714-14.